IFNB1 and myeloid sarcoma: Accordingly, we previously demonstrated that untreated-MS patients had lower sIFNAR2 levels than healthy controls, patients with other inflammatory neurological diseases and MS patients treated with IFN-β, highlighting its value as a diagnostic biomarker for MS.